UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~August~~January 249, ~~2022~~2023

Commission file number: 1-03319

Quad M Solutions, Inc.

Idaho		82-0144710
(State or Other Jurisdiction of Incorporation of Organization)		(I.R.S. Employer Identification Number)

1111 Beltline Road, Suite 108E, Garland, TX		75040
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, including area code: (877) ~~367~~465-~~9199~~8080

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 58.0201 ~~Departure~~Other ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Events.

Quad M Solutions, Inc., ~~an Idaho corporation,~~ (the “Company” ~~or “Registrant”~~), is afiling ~~public~~as ~~holding~~Exhibit ~~company~~99.1 ~~(OTC:~~to ~~MMMM) is filing~~ this ~~Current Report on~~ Form 8-K toa ~~report~~Press ~~that~~Release atdated aJanuary ~~meeting~~9, of2023, ~~its~~reporting that ~~Board~~the ofCompany ~~Directors~~approved ~~(“Board”)~~the onmigration ~~August~~of ~~24,~~one ~~2022, at~~of ~~which~~the ~~meeting~~largest ~~all~~group of ~~the~~clients ~~members~~ of ~~the~~its ~~Board~~wholly ~~were~~owned ~~present~~subsidiary, inNuAxess ~~person~~2, ~~and/or~~Inc. ~~telephonically~~(“NuAxess”), to ~~the~~a ~~Board~~third-party ~~unanimously~~insurance ~~approved~~company. Under the ~~appointment~~ terms of ~~Drs.~~this ~~Michael Fonstein~~transaction, ~~Ph.D.~~NuAxess ~~and~~assigned ~~Yakov~~over ~~Kogan,~~500 ~~Ph.D.~~staffed toemployees’ contracts from NuAxess for the ~~Company’s~~cash ~~Board~~value of approximately $5 million.

~~Dr.~~In ~~Michael~~addition, ~~Fonstein~~the ~~PhD,~~Company’s ~~age~~Board ~~62,~~of ~~Director:~~Directors ~~Dr.~~reviewed ~~Michael~~the ~~Fonstein~~interim ~~was~~results ~~appointed~~of asthe aongoing ~~director~~internal ofaudit ~~Quad~~led Mby ~~Solutions,~~Yakov ~~Inc.~~Kogan, ana ~~Idaho~~member ~~corporation~~of ~~(OTC:~~the ~~MMMM)~~Company’s onBoard ~~August~~and ~~24,~~COO ~~2022.~~of ~~In 2021~~NuAxess, ~~Dr.~~of ~~Fonstein~~existing ~~founded~~NuAxess ~~and~~staffing ~~has~~agreements ~~served~~from as2020 ~~Chairman~~through ~~and CEO of BioSynthetic Machines~~2022, ~~Inc.,~~which anreview ~~Illinois-based~~has ~~company organized under~~ led the ~~laws~~Board ofto ~~Nevada~~conclude ~~(“BSMI”).~~that ~~Dr. Fonstein~~there ~~has~~is ~~also~~sufficient ~~founded~~evidence ~~and~~that ~~served~~material asmisrepresentations ~~CEO~~ of ~~several~~all ~~biotechnology~~clients ~~companies~~accurate ~~including:~~medical ~~Integrated~~history ~~Genomics, Inc., Cleveland~~have ~~Biolabs,~~been ~~Inc.,~~made ~~n/k/a~~to ~~Statera~~NuAxess ~~Biopharma,~~by ~~Inc.~~certain ~~(NASDAQ: STAB), a clinical~~third-~~stage biopharmaceutical~~party ~~company developing novel immunotherapies targeting autoimmune~~clients, ~~neutropenia/anemia~~referrers, ~~emerging viruses~~ and ~~cancers based~~vendors onin ~~a proprietary platform designed to rebalance~~ the ~~body’s~~Special ~~immune~~Risk ~~system~~Questionnaires ~~and restore homeostasis; Accelerated Pharma~~(“SRQ”), a ~~Inc.~~prerequisite ~~and~~to ~~Panacela~~NuAxess ~~Labs,~~accepting ~~Inc.,~~the ~~private~~staffing ~~Delaware companies~~agreements. ~~Through~~These ~~his management~~misrepresentations, ~~several~~the ofCompany ~~these~~firmly ~~companies developed from start-ups to established and successful ventures~~believes, ~~securing~~warrants ~~multiple rounds of private and public financing including R&D and~~immediate ~~service~~termination ~~contracts with Fortune 100 companies and procurement~~ of ~~governmental~~the ~~grants~~associated ~~among~~staffing ~~other funding~~agreements. ~~Dr.~~Due ~~Fonstein~~to ~~has~~such ~~extensive business~~material ~~and~~misrepresentations, ~~scientific~~NuAxess ~~experience~~has ~~and~~taken ~~actively~~action ~~involved day-~~to~~-day~~ ~~operations~~limit asits ~~well as strategic corporate planning of the~~financial ~~businesses~~damages ~~he founded. Dr. Fonstein started his career as a research scientist. During his years in academia, Dr. Fonstein became a recognized expert in microbial genomics~~ and ~~system~~terminate ~~biology, founded a genomic center at~~ the ~~University~~underlying ofstaffing ~~Chicago, and published numerous papers in top peer-reviewed scientific journals~~agreements. ~~Most recently Dr. Fonstein served as a Computational Scientist at U.S. Department of Energy’s Argonne National Laboratory.~~

~~Dr.~~The ~~Yakov~~Company ~~Kogan, Ph.D., age 49, Director: Dr. Kogan was appointed as a director of Quad M Solutions, Inc., an Idaho corporation (OTC: MMMM) on August 24, 2022. Dr. Kogan co-founder and~~ has ~~served~~engaged ascounsel ~~Chief Business Officer of BSMI from 2021~~ to ~~the~~pursue ~~present.~~legal ~~Prior~~remedies toagainst ~~joining~~those ~~BSMI,~~clients ~~Dr.~~and/or ~~Kogan~~referrers ~~served~~who ashave amisrepresented ~~senior~~material ~~consultant~~facts to NuAxess ~~several private~~ and ~~public~~thereby ~~biotechnology companies~~caused ~~including:~~damages ~~serving~~to asNuAxess abusiness ~~CEO~~ and ~~director~~its ofother ~~Cleveland BioLabs, Inc~~clients., ~~n/k/a~~NuAxess ~~Cytocom,~~has ~~Inc.~~also ~~(NASDAQ:~~instructed ~~CBLI) together with Dr. Fonstein, which they had built from~~ its ~~inception~~counsel to ancommence ~~operation with over 50 full-time employees, while securing upward of $150 million in equity~~collection ~~financing.~~actions ~~During~~for ~~his tenure with CBLI, Dr. Kogan played a significant role in establishing operations, hiring senior operations staff, and executing~~ the ~~Company’s~~uncollected ~~initial~~staffing public offering on NASDAQ. Prior to CBLI, Dr. Kogan served as Director for Business Development at Integrated Genomics, a private company located in Chicago, IL, where he was responsible for commercial sales and ~~expansion~~late offees ~~the company’s~~during capital base. Prior to his position as Director of Business Development, Dr. Kogan worked as a Group Leader/Senior Scientist at Integrated Genomics as well as at ThermoGen, Inc. In addition, Dr. Kogan was a Research Associate at the ~~University~~period offrom ~~Chicago~~2020-2022, ~~where he~~among ~~led~~other ~~the execution of several sophisticated microbial genome sequencing projects~~remedies.

~~Dr.~~NuAxess ~~Kogan~~will ~~holds~~continue aefforts ~~Ph.D.~~to ~~degree~~pay inall ~~Molecular~~valid, ~~Biology~~documented ~~from~~costs ~~VNII~~presented ~~Genetica~~by ~~(State~~clients ~~Research~~who ~~Institute~~have oftruthfully ~~Genetics~~responded ~~and~~to ~~Selection~~SRQs ofand ~~Industrial Microorganisms~~otherwise acted in ~~Moscow,~~good ~~Russia),~~faith. asIn ~~well~~order asto anprotect ~~M.S.~~the ~~degree~~Company inand ~~Biology~~its ~~from~~shareholders, ~~Moscow~~NuAxess ~~State~~will ~~University~~not ~~and~~commit anfunds ~~MBA~~to ~~degree~~cover ~~from~~any ~~the~~liabilities ~~University~~where misrepresentations were made to obtain the services of ~~Chicago~~NuAxess.

InThe ~~connection~~Company ~~with~~is ~~the~~resuming ~~appointments~~its ofself-funded ~~Drs.~~plan ~~Fonstein~~for ~~and~~2023 ~~Kogan,~~through ~~Mr.~~a ~~Douglas~~new ~~Cole,~~third-party ~~who~~administrator ~~served~~to asprovide acontinued ~~Director~~services for its clients and employees. With the completion of ~~Quad~~our Monboarding ~~Solutions~~technology, ~~Inc.~~better authentication and compliance, ~~stepped~~the Company is focused on growing ~~down~~its asstaffing business at a ~~member~~more ofsustainable ~~its~~growth ~~Board~~rate. In addition, the Company has identified and ~~was~~intends ~~appointed~~on asmaking aseveral ~~member~~strategic acquisitions ofover the ~~Company’s~~coming ~~Advisory~~months ~~Board.~~to Mrrealize additional revenue. ~~Cole~~This ~~did~~includes ~~not~~acquisitions ~~have~~of ~~any~~complementary ~~disagreements~~services specifically ~~with~~targeted ~~the~~at ~~operations,~~providing ~~policies~~security orand ~~practices~~verification ofmethods in order to better insulate the Company ongoing ~~any matters~~forward.

Reference is made to the full disclosure contained in the Press Release dated January 9, 2023, attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits

(b) The following documents are filed as exhibits to this current report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

Exhibit No.		Description
99.1		Quad M Solutions Press Release dated January 9, 2023, filed herewith.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: ~~August~~January 249, ~~2022~~2023

	QUAD M SOLUTIONS, INC.

	By:	/s/ Joseph Frontiere
		Joseph Frontiere
		Chief Executive Officer

Filing Compare · Quad M Solutions, Inc.